724-98-1

Basic information

• Product Name: 2-(Phenoxymethyl)benzoic acid
• Synonyms: 2-(phenoxymethyl)-benzoicaci;Benzoic acid, 2-(phenoxymethyl)-;TIMTEC-BB SBB008075;ALPHA-PHENOXY-O-TOLUIC ACID;2-(PHENOXYMETHYL)BENZOIC ACID;o-(phenoxymethyl)benzoic acid;α-Phenoxy-o-toluic acid;EINECS 211-967-5
• CAS NO: 724-98-1
• Molecular Formula: C₁₄H₁₂O₃
• Molecular Weight: 228.24
• EINECS: 211-967-5
• Product Categories: Organic acids
• Mol File: 724-98-1.mol
• Article Data: 15

Chemical Properties

• Melting Point: 126°C
• Boiling Point: 392.5 °C at 760 mmHg
• Flash Point: 150.6 °C
• Appearance: /
• Density: 1.222 g/cm³
• Vapor Pressure: 7.29E-07mmHg at 25°C
• PKA: 3.85±0.36(Predicted)
• CAS DataBase Reference: 2-(Phenoxymethyl)benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(Phenoxymethyl)benzoic acid(724-98-1)
• EPA Substance Registry System: 2-(Phenoxymethyl)benzoic acid(724-98-1)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• TSCA: Yes
• Hazardous Substances Data: 724-98-1(Hazardous Substances Data)

Usage

General Description

2-(Phenoxymethyl)benzoic acid is a chemical compound with the molecular formula C15H14O4. It is a derivative of benzoic acid, where a phenoxymethyl group is attached to the benzene ring. 2-(Phenoxymethyl)benzoic acid has potential pharmaceutical applications due to its anti-inflammatory and analgesic properties. It is also used in the synthesis of various organic compounds. 2-(Phenoxymethyl)benzoic acid is a white crystalline powder that is sparingly soluble in water and soluble in organic solvents. It is important to handle this compound with care, as it may cause irritation to the skin, eyes, and respiratory system.

InChI:InChI=1/C14H12O3/c15-14(16)13-9-5-4-6-11(13)10-17-12-7-2-1-3-8-12/h1-9H,10H2,(H,15,16)/p-1

Upstream product

• 94191-73-8 1-bromo-2-(phenoxymethyl)benzene 
• 866996-44-3 methyl 2-(phenoxymethyl)benzoate 
• 87-41-2 2-benzofuran-1(3H)-one 
• 139-02-6 sodium phenoxide 
• 7115-91-5 2-ethoxycarbonylbenzyl bromide 
• 108-95-2 phenol 
• 2417-73-4 methyl 2-bromomethylbenzoate 
• 3433-80-5 1-Bromo-2-bromomethyl-benzene 
• 59567-93-0 diazomethane 
• 124-38-9 carbon dioxide 
• 18982-54-2 o-bromobenzyl alcohol 
• 578-51-8 2-bromobenzylchloride 
• 89-71-4 2-Methyl-benzoic acid methyl ester 
• 34040-62-5 o-(chloromethyl)benzoic acid methyl ester 

Downstream Products

• 34904-98-8 2-phenoxymethyl-benzyl alcohol 
• 4504-87-4 6,11-dihydrodibenz[b,e]oxepin-11-one 
• 87-41-2 2-benzofuran-1(3H)-one 
• 108-95-2 phenol 
• 176509-37-8 (2-Phenoxymethyl-benzoyl)-phosphonic acid dimethyl ester 
• 1229-29-4 doxepin hydrochloride 
• 114312-42-4 1-(6,11-Dihydro-dibenzo[b,e]oxepin-11-yl)-4-((E)-3-phenyl-allyl)-piperazine; compound with (Z)-but-2-enedioic acid 
• 139305-71-8 1-(6,11-Dihydro-dibenzo[b,e]oxepin-11-yl)-4-(3-phenyl-prop-2-ynyl)-piperazine; compound with (Z)-but-2-enedioic acid 
• 77175-92-9 (2-chloromethyl-benzyl)-phenyl ether 
• 21733-94-8 2-phenoxymethylbenzoyl chloride 
• 1354017-80-3 C₃₃H₄₃NO₄S 
• 1354017-70-1 (R)-2-(2-(phenoxymethyl)benzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)propanoic acid 

Relevant articles and documents

Preparation method of benzyl aryl ether and application of benzyl aryl ether in synthesis

and, 6-dihydrodibenzo [11 - b] oxazepine e -11 - ketone compounds are synthesized through a one-step reaction of benzaldehyde compounds and phenolic compounds through one-step reaction. The benzyl aryl ether and 6 and 11 -dihydrodibenzo [b, e] oxazepine -11 - ketone compound respectively have a chemical structure formula shown in a formula I and II. The invention discloses a synthesis method of the compound. Benzaldehyde compound After completion of the reaction, I, 6-dihydrodibenzo [11 - b] oxazepine e ketone compound -11 - can be synthesized through an oxidation or hydrolysis step and a ring closing step after the reaction is complete II.

Iron(II) promoted direct synthesis of dibenzo[b,e]oxepin-11(6H)-one derivatives with biological activity. A short synthesis of doxepin

A novel and efficient synthesis of dibenzo[b,e]oxepin-11(6H)-ones by direct intramolecular ortho-acylation from readily available 2-(phenoxymethyl)benzoic acids was developed. The method takes advantage of a newly developed cooperative system consisting of sustainable FeCl2 and Cl2CHOCH3 as the key components. This methodology is compatible with a wide variety of functional groups in good to excellent yields and high regioselectivity. The synthetic application of new protocol was extended to the synthesis of known tricyclic drug doxepin as well as a small library of oxepin based derivatives. For the first time, the obtained dibenzo[b,e]oxepinone derivatives were evaluated for their biological activities on the free-living nematode Caenorhabditis elegans as an effective and cost-efficient model system for anthelmintic discovery.

Dibenzo[b,f][1,4]oxazepines and dibenzo[b,e]oxepines: Influence of the chlorine substitution pattern on the pharmacology at the H1R, H4R, 5-HT2AR and other selected GPCRs

Inspired by VUF6884 (7-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine), reported as a dual H1/H4 receptor ligand (pKi: 8.11 (human H1R (hH1R)), 7.55 (human H4R (hH4R))), four known and 28 new oxazepine and related oxepine derivatives were synthesised and pharmacologically characterized at histamine receptors and selected aminergic GPCRs. In contrast to the oxazepine series, within the oxepine series, the new compounds showed high affinity to the hH1R (pKi: 6.8–8.7), but no or moderate affinity to the hH4R (pKi: ≤ 5.3). For one oxepine derivative (1-(2-Chloro-6,11-dihydrodibenzo[b,e]oxepin-11-yl)-4-methylpiperazine), the enantiomers were separated and the R-enantiomer was identified as the eutomer at the hH1R (pKi: 8.83 (R), 7.63 (S)) and the guinea-pig H1R (gpH1R) (pKi: 8.82 (R), 7.41 (S)). Molecular dynamic studies suggest that the tricyclic core of the compounds is bound in a similar mode into the binding pocket, as described for doxepine in the hH1R crystal structure. Moreover, docking studies of all oxepine derivatives at the hH1R indicate that the oxygen and the position of the chlorine in the tricyclic core determines, if the R- or the S-enantiomer is the eutomer. For some of the oxazepines and oxepines the affinity to other aminergic GPCRs is in the same range as to hH1R or hH4R, thus, those compounds have to be classified as dirty drugs. However, one oxazepine derivative (3,7-Dichloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine was identified as dual hH1/h5-HT2A receptor ligand (pKi: 9.23 (hH1R), 8.74 (h5-HT2AR), ≤7 at other analysed GPCRs), whereas one oxepine derivative (1-(3,8-Dichloro-6,11-dihydrodibenzo[b,e]oxepin-11-yl)-4-methylpiperazine) was identified as selective hH1R antagonist (pKi: 8.44 (hH1R), ≤6.7 at other analyzed GPCRs). Thus, the pharmacological results suggest that the oxazepine/oxepine moiety and additionally the chlorine substitution pattern toggles receptor selectivity and specificity.